Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 13, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Company’s Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing All Six Target Clinical Sites are on Track to be Fully Opened by Year End ASHBURN, Va., Dec. 13, 2022 ...
November 10, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results

Company completed a public offering for aggregate gross proceeds of $16.8 millionMajority of clinical sites now open in clinical study to evaluate QRX003 for Netherton SyndromeQuoin announced plans to...
November 03, 2022 07:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th

ASHBURN, Va., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
November 01, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th

ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
October 18, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients

ASHBURN, Va., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases,...
September 13, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study

ASHBURN, Va., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has...
August 18, 2022 07:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results

Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton SyndromeExpands number of commercial partnerships to eight, covering 60 countriesSigns Research Agreement to develop a...
August 11, 2022 16:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th

ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
August 09, 2022 16:23 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering

ASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
August 05, 2022 09:28 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering

ASHBURN, Va., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...